http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0780125-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_850a17186ff51f03c607cf42a534a635 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P39-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4166 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4166 |
| filingDate | 1996-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2001-04-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_77148558bf149ec42ee74828196e0604 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_66261e522e7a8d137b948d5144909b3d |
| publicationDate | 2001-04-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-0780125-B1 |
| titleOfInvention | Use of hydantoin derivatives for the preparation of a medicament for the treatment of dieases associated with the presence of active oxygen and free radicals |
| abstract | The present invention is directed to a pharmaceutical composition comprising a hydantoin derivative represented by the following formula (I) or a pharmaceutically acceptable salt thereof <CHEM> wherein each of R1 and R2, which may be the same or different, represents hydrogen, an alkyl group or a cycloalkyl group; and each of X and Y, which may be the same or different, represents hydrogen, hydroxyl group, an alkyl group or an alkoxy group, or X and Y together represent an oxo group, and a pharmaceutically acceptable carrier or diluent. The above mentioned hydantoin derivative has an action of eliminating the active oxygen and the free radicals. Accordingly, it is useful for preparing a pharmaceutical agent for treating a variety of diseases in which active oxygen and free radicals are participated such as myocardial infarction, reperfusion disturbance, autoimmune diseases, fibrosis, pulmonary diseases, dermatological diseases, arthropathy, side effects of anticancer agents, radiation diseases, septic shock, inflammatory diseases and cataract. |
| priorityDate | 1995-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 319.